Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes yes ruck - it’s based on hope rather than certainty, as are many things in life. We are all “hoping” together. Lovely. The point of my post was to shed some light, or trigger some discussion, about the nature or degree of the uncertainty.
Wiggy, I really hope you are right.
Risks and scenarios. The board appear to be downplaying expectations for the GC, and having delayed the scib trial one can fear they may do it again. But even under this scenario (which I consider improbable), what is the outcome? First, they retain the £5m they would have spent on scib1 and reinforce the balance sheet. Second, they consolidate the chances that the first clinical moditope trial is funded to completion. In the days running up to the moditope result - the first clinical readout of one of the most promising preclinical cancer discoveries in history , 12-18 months from now, I can see the market cap north of £200m - it is a unique and exciting story and is likely to capture the imagination of the market. Regarding trial risk itself - a different type of uncertainty and a different level of return - but there may well be fun and games played out before we get there :)
True, but that could be delays unforseen by new disoveries in clinical development, alongside with our collaborators too. awahich is why i still say criticisms of the BOD are unfair for a very simple reason..........we do not know exactly what is going on for now.
I get what your getting at, i felt it myself, but that was largely out of frustration, lets see what comes out that the company couldn"t discuss. Goodnight.
"...Delays are part and parcel of a small bio but when a BOD develops a habit of them then it is frustrating."
This x 100.
It is funny though we get very few posts where investors do not believe in the science any more just a reality that comes with humility remembering our current share price.. In a year where we have seen 19p and now 7p, confidence does get hit, we all look for what we are missing/missed, i just think in this market a good run of news will see us rise pretty quickly.
Being positive in our outcomes due to the lack of negative posts IMHO, and i think what has been seen largely by delays is actually clinical improvement/development which the timelines were not thought to be so long by many of us. Going in to 2019 with news of SCIB 1 IND , GC results, and the unusual situation of investors having had a good two years working with us for mutual benefit.Even the extension to the Karolinska Institute is more than welcome, and we seem to be in a very tight circ;e, the new CEO of Oncimmune is Peter Johnson (Univ of Sotom) and another Board member from Karolinska, lets just compare that to three years ago in terms of strategy, and potential areas of major news. Newbies are buying in at low prices, we are topping up at low prices, and the potential upside is exciting compared to the downside and possibilities. Lets hope that starts translationg into the IP in the coming months.
C7/DA -agree on points re negativity but when the SP just drifts to very low levels then some people start doubting the fundamentals and yes there is more the BOD could do even if it is just communicating more.
On all my LTH I have the same policy to hold long and strong except if the science changes or if the BOD did something which caused me to not trust them always taking I to account their cash position.
Delays are part and parcel of a small bio but when a BOD develops s a habit of them then it is frustrating.
C7 yes fully u derstand your need to focus on other stuff but equally know what pleasure you get from posting here as well
Ivy,
Just wanted to clarify that when i say i have written off my investment, it is just my way of taking Scancell away from being my focus. At 50p even if i sold that would bring in £72,500, that would come in very handy indeed.
DA I think you explained that rather well in the previous post, hich kind of answers why there has been not so much negativity, but reasoned posts by many. ATB all.
I personally am a little bit surprised by the recent negativity, purely because of news of both the Cancer Research UK Grand Challenge and more importantly (IMO) the Ichor/IND approval should be a matter weeks away now,right? I do feel this is on the cusp...a major turning point now, certainly as 2019 starts, and maybe even something sooner this week RE the IND. (However I appreciate that I and many of is have felt that before too!)
Being a long term holder I do however 100% share the (huge) frustration that several of us do on here are, and still think the BOD could and should have done more in the meantime (IMO).
C7
Agree they will release news when ready but some PIs will sell either because they need to for say Xmas or they are bored or worried it will fall further etc and of course in any illiquid share it does not take much volume to drop it further.
Know you understand this better than most as you have more knowledge of the market.
Hope you are well
Feel very similar Ivy, on all points, said last year really I had mentally written off my investment here, but still had the dream we would come good eventually, and funny enough I was only disagreeing with some criticism of the BOD, because on the other hand they have given LD all the time she needs for clinical development, which is essential as we have no room for errors in trials.
Just been rather surprised at our weakness the last couple of months falling back again from the 10s to 7s. My average is 17p now, not exactly happy with that, but the route back to the 20s is realistic with news and trials ever approaching nearer. Lets hope we have bottomed out, just about, wonder if we will be subject to a share tip or two before the NEW year?
Morning
TF inclusive lol.
RR-especially in today’s AIM market where unless you moved to cash you are likely to be suffering big losses as the much reduced liquidity due to effects of Beaufort/Crypto Currency etc in conjunction with all the adverse macro factors like Brexit/China and US trade situation effect things.
In SCLP which has a much higher PI base and no news has led to a perfect storm for a declining SP.Certain virtually everyone agrees that the true value is a long way North of here but it is the confirmation of this potential in actual trial progress results that will be the game changer here.
Until then we all have to accept the value of our shares is only what someone will pay and at today’s prices not very much.
Like you I will not sell any at today’s low levels but neither will I add until the bottom is in.
Very happy with my exposure here and can afford to wait long enough for the science to determine the outcome here.
Funny old game when rhatton sold his holding at 11.5p or whatever and dud so reluctantly.
In hindsight seems a very shrewd move and hope he has/ does buy back in as the science story is as strong as ever just need progress on starting these trials
Ivy, you are spot on! I think I get some stick because I am too open and honest and as you say we will all feel differently about a certain situation. This is why I get annoyed when people tell you not only what you should do but how you should feel.
Imo this is what a BB should be about honest expression of views but also being tolerant of the fact that every one’s circumstances/attitude to risk/knowledge and understanding of a particular share and of investing on AIM is different.
That is why people often disagree as their agenda,experience,knowledge,trust,length of investment perspective,ability to make sound decisions is very individual.
Listen to no one and make your own decisions based on your own research and try not to think of the SP as being reflective of true value but at the same time accepting that the SP does reflect value at any particular point in time.
But hopefully tonight does reflect a much more includpdive board
,